Fatigue is common in cancer survivors but often insufficiently treated. Due to its complexity a one-size-fits-all treatment seems not appropriate. To gain more information on influencing factors and sub-dimensions of fatigue we investigated potential determinants and correlates of physical, affective, and cognitive fatigue in breast cancer survivors during and after adjuvant therapy. Within the follow-up of two randomized controlled trials physical, affective, and cognitive fatigue were repeatedly assessed during and up to 12 months after cancer therapy with the 20-item Fatigue Assessment Questionnaire in 255 breast cancer survivors. Determinants of the different fatigue dimensions over time were explored with linear mixed models. Chemotherapy appeared as significant precipitating factor for physical fatigue. However, type of cancer therapy had no impact on fatigue one year post-treatment. Obesity was significantly associated with increased physical fatigue throughout all time points (D515.5 at 12 months) whereas exercise appeared to be beneficial (D 5 26.3). In contrast, affective fatigue was significantly associated with poor social support and worries about the future. In addition, poor sleep quality and previous use of psychopharmaceuticals were significantly associated with physical, affective, as well as cognitive fatigue. Further, hot flashes were associated with increased physical and cognitive fatigue. In conclusion, the broad diagnosis 'fatigue' in cancer survivors needs to be recognized as a diversity of symptoms determined by specific characteristics and likely different etiologies. Taking potential influencing factors such as obesity, physical inactivity, sleep problems, hot flashes, lack of social support, or psychological disorders into consideration might enable a better, individually-tailored fatigue treatment.
Introduction
Fatigue is a major concern during and after breast cancer therapy with severe impact on quality of life. 1, 2 Cancerrelated fatigue has been defined as 'a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning'. 3 So far, its pathophysiology is not well understood. There is no clearly effective drug and fatigue often remains insufficiently treated. 4 Yet, fatigue in cancer patients may need to be better defined or differentiated. Thus far, it is well accepted that fatigue manifests itself in different dimensions, described by cancer patients as physical, affective, and cognitive sensation of tiredness. 5, 6 Moreover, it is unclear whether or not the different dimensions of fatigue are expressions of a single symptom or rather several distinct phenomena with different pathogeneses that are just all commonly named fatigue by patients and professionals. 2, 7 This hypothesis is supported by a systematic review that found that patterns of physical fatigue during therapy differed from that of mental (i.e. cognitive or affective) fatigue, and that interventions affected physical and mental fatigue differently. 7 However, investigations of correlates of the separate fatigue dimensions are scarce. 2, 7 In addition, a clearer distinction might be necessary between fatigue that is associated with the cancer or its treatment, and fatigue caused by pre-existing conditions. 8, 9 It is also still up to discussion what determines fatigue persistence after termination of cancer therapy, and whether persistent fatigue is primarily a consequence of cancer. 8, 10 Disentangling such symptoms with different pathophysiologies subsumed under the term cancer-related fatigue would be a major step towards the development of effective treatments tailored to the individual patient's needs. Therefore, we investigated correlates and determinants of physical, affective, and cognitive fatigue during and after adjuvant therapy within the framework of two prospective trials.
Material and Methods

Study design and population
The BEATE-Study and BEST-Study were randomized controlled exercise intervention trials with primary endpoint fatigue in breast cancer patients conducted in parallel between 2010 and 2013 at the National Center for Tumor Diseases (NCT) Heidelberg, Germany. Details of the designs and primary results are published. [11] [12] [13] [14] Since the interventions, the assessment of fatigue and the investigated covariates were identical across both studies, data could be pooled for the present analyses. Patients had been randomized either to 12-week resistance exercise or relaxation control (Jacobson method 15 ) concomitant to adjuvant chemotherapy (BEATE) or radiotherapy (BEST). Both studies were approved by the ethics committee of the University of Heidelberg (S-012/2009, S-447/ 2010) and registered at ClinicalTrials.gov (NCT01106820, NCT01468766). Assessments were prior (T0), mid (T1, Week 7) and end of intervention (T2, Week 13), and 2-3 months (T3), 6 months (T4, BEST only), and 12 months (T5) postintervention. In BEATE adjuvant chemotherapy had started shortly (1-2 cycles) prior to T0 and typically ended around T2. In BEST adjuvant radiotherapy started after T0 and ended at T1, whereby a third of patients had undergone chemotherapy before T0. Informed consent was obtained from all individual participants included in the study.
Assessment of fatigue
Fatigue was self-assessed with the 20-item Fatigue Assessment Questionnaire (FAQ) that was developed and validated for cancer patients. 16 It covers the physical, affective and cognitive fatigue dimensions. Scores were derived by adding the answers (0 5 not at all to 3 5 very much) and linearly rescaled to a 0-100 scale. Additionally, pre-diagnosis fatigue was rated retrospectively on a scale from 0 (not tired at all) to 10 (totally exhausted).
Assessment of covariates
Socio-demographics (age, education, marital and living status), concomitant diseases, concomitant medication, smoking, tumor characteristics, and cancer treatment were recorded by questionnaire or extracted from the medical charts. Body mass index (BMI) was calculated from height and weight, measured in a standardized way, as kg/m 2 . Typical adverse symptoms were assessed with the EORTC QLQ-C30 and -BR23 such as pain, breast problems, hot flashes and worry about the future, and categorized as 'high' if rated as 'quite a bit' or 'very much'. The 20-item Center for Epidemiological Studies Depression Scale (CES-D) was used to measure depressive symptomatology. 17 Perceived social support was assessed by the multidimensional scale of perceived social support (MSPSS) and categorized as good support if above 75% on a scale of 0-100%. 18 Sleep quality was assessed with a single 4-level Likert item ('How would you rate your overall sleep quality in the last week?'), and categorized as 'high' if rated 'rather good' or 'very good'.
Statistical methods
Linear mixed effects models for repeated measurements were used to explore potential determinants of physical, affective, and cognitive fatigue, respectively. Based on possible or plausible associations the models included at least one factor of each of the following groups that were explored as potential determinants: age-related factors (age continuous, age categorized, menopausal status); cancer or treatment characteristics (tumor stage, receptor status, type of surgery, chemo-or radiotherapy, hormone therapy); socio-demographic factors (education, living alone or with others, social support); baseline BMI; adverse symptoms (hot flashes, breast problems); current sleep quality; pre-existing medical conditions (baseline use of psychopharmaceuticals, cardiovascular diseases, thyroid disorders), and smoking status at baseline (no smoking/quit last year/current smoking). In case of collinear variables only the stronger determinant was kept in the final model. Adjusted mean differences (D) with the corresponding 95% confidence intervals were derived from the linear mixed models including age (continuous), triple negative tumor (yes/no), hormone therapy (yes/no), therapy at baseline (previous chemotherapy/ current chemotherapy/no chemotherapy), social support (low/ high), baseline BMI (<25/25-30/30), hot flashes (low/high), worries about future (low/high), sleep quality (low/high), previous use of psychopharmaceuticals (yes/no), smoking status What's new? Cancer-related fatigue can be highly distressing for patients but is still often insufficiently treated. In order to improve therapy, however, more must be learned about the origins and development of fatigue. Here, investigation of fatigue in breast cancer survivors via longterm follow-up during and after cancer therapy reveals a range of fatigue-associated symptoms, including hot flashes, lack of social support, physical inactivity, obesity, and psychological and sleep disorders. The diversity of symptoms suggests a similarly diverse array of etiological origins for fatigue, likely necessitating an individualized approach to patient care to effectively treat the condition.
(current/quit/no smoking), intervention group (exercise/control), any further exercise (yes/no), and the pre-diagnostic fatigue rating (scale 0-10). Depressive symptoms and pain were not included in the final models as they were highly correlated with fatigue but causal direction was ambiguous. However, adding pain or depressive symptoms to the models did not change the results markedly. Statistical tests were twosided, and p < 0.05 was considered statistically significant. SAS Version 9.3 was used.
Results
Of the 261 patients enrolled in BEST (160) and BEATE (101), n 5 255 patients with apparently disease-free survival at follow-up were included in the analysis. Of the other 6 patients, 1 had died, 3 had metastases, 1 recurrence, and 1 dropped out after randomization without any fatigue measures. Fatigue assessments were available in n 5 240 (94.1%) at T1, n 5 248 (97.3%) at T2, n 5 235 (92.2%) at T3, n 5 148 (93.1% of BEST only) at T4 and n 5 225 (88.2%) at T5. Baseline characteristics are presented in Table 1 .
Time course of fatigue
Physical fatigue among chemo-and radiotherapy-na€ ıve patients after surgery was slightly higher compared to healthy German women 16 of comparable age (mean: 34.5 vs. 30.3 on the 0-100 scale). In patients having received 1-2 chemotherapy cycles physical fatigue was even higher (40.2) and further increased until the end of chemotherapy in the control group (49.1) whereas in the exercise group it remained stable (40.5). At 12-month follow-up patients' physical fatigue levels were comparable to the healthy population (30.4), irrespective of intervention group. Physical fatigue at end of radiotherapy was increased in both intervention groups (45.1), but subsequently declined again until 12-month follow-up (32.7).
Affective fatigue was already higher among therapy-na€ ıve patients after surgery compared to healthy persons (median 5 33.3 vs. 13.3, Q3 5 50.0 vs. 33.3) and remained elevated throughout all timepoints irrespective of intervention group. Cognitive fatigue showed a similar course but some more fluctuations. A cross-sectional difference between 13 and 19 has been considered as median clinically relevant difference for a similar 0-100 fatigue scale. 19 Correlations between fatigue dimensions, depressive symptoms and pain Spearman correlations between the different fatigue dimensions, depressive symptoms and pain at 12-month follow-up are presented in Table 2 . Physical fatigue correlated with affective fatigue (r50.66), cognitive fatigue (r50.64), depressive symptoms (r 5 0.67) and pain (r 5 0.59), all p<0.0001.
Determinants of physical fatigue
Linear mixed models on physical fatigue (Table 3 ) revealed a significant interaction between adjuvant treatment and time (p<0.0001): Physical fatigue was significantly higher in patients during chemotherapy than without current therapy (i.e. at T0: current chemotherapy vs. no chemotherapy; at T2: around end of chemotherapy vs. 6 weeks after completion of radiotherapy).
The exercise intervention showed a borderline significant interaction with time (p 5 0.057): Physical fatigue was significantly lower in the exercise group compared to the Higher BMI at baseline was consistently associated with increased physical fatigue during and after cancer treatment (main effect p 5 0.0001). In contrast, pre-diagnosis physical fatigue levels were comparably low across all three BMI categories (p 5 0.72) with a median of 1 on the 0-10 scale.
Further, physical fatigue was strongly associated with use of psychopharmaceuticals at baseline, poor sleep quality, and worries about the future (all p<0.0001). Hot flashes also showed a significant association (p 5 0.003) with a fluctuating pattern over time (time interaction p 5 0.080). Age was not significantly associated with physical fatigue (p 5 0.15).
Determinants of affective fatigue
In contrast to physical fatigue, neither chemotherapy, the exercise intervention nor self-reported exercise were significantly associated with affective fatigue and there were also no significant interactions with time (Table 4) . BMI showed a significant interaction with time (p 5 0.032), with higher affective fatigue among obese women only at follow-up. Smoking (p 5 0.0003) and poor social support (p 5 0.0010) were significantly associated with increased affective fatigue.
Comparable to physical fatigue, psychopharmaceuticals, poor sleep quality, and worries about the future were significantly associated with affective fatigue.
Determinants of cognitive fatigue
Strongest determinants of cognitive fatigue were use of psychopharmaceuticals (p 5 0.0015) and poor sleep quality (p<0.0001, time interaction p 5 0.052). Obesity was positively associated with increased cognitive fatigue (p 5 0.043) especially post-intervention (Table 5) .
Baseline use of psychopharmaceuticals
Patients with psychopharmaceuticals use (n 5 23) had higher physical and cognitive fatigue throughout all timepoints (Fig.  1, red line) , and had also higher pre-diagnosis fatigue levels compared to the other patients (median (Q1, Q3) 5 3(1, 4) vs. 1(0, 3) on the 0-10 scale, p 5 0.051). Additionally, depression scores were significantly higher at each timepoint.
Sensitivity analyses excluding those patients from the mixed models showed no substantial changes in results. Figure 1 further illustrates the potential impact of obesity and the effect of the exercise intervention on the patterns of physical, affective, and cognitive fatigue.
Discussion
We have identified correlates and potential influencing factors of fatigue during and after adjuvant breast cancer therapy, which differed between the physical, affective, and cognitive dimension. Moreover, fatigue during cancer therapy was in part determined by other factors than fatigue several months post-treatment. Thus, cancer-related fatigue needs to be considered differentiated, as discussed below.
Chemotherapy had previously been identified as precipitating factor of fatigue. 4 Yet, the influence on different dimensions of fatigue have been rarely studied. 7 Our data showed a significant impact of chemotherapy only for physical but not for cognitive or affective fatigue. Another study in breast cancer patients also observed an increase in physical fatigue over the course of chemotherapy but no clear pattern of mental fatigue. 20, 21 In line with previous observations, chemotherapy showed no significant impact on physical fatigue about one year post-treatment. 8 The biological mechanisms are still unclear. In our studies physical but not affective or cognitive fatigue were associated with dysregulations of the diurnal cortisol rhythm, which might be a consequence of chemotherapy. 22 Decreased cardiopulmonary function after chemotherapy, might also contribute to physical rather than mental fatigue. 23 As reported in the primary analyses of BEATE and BEST, 13, 14 the resistance exercise intervention concomitant to adjuvant chemo-or radiotherapy had significant benefits on physical fatigue during and directly after therapy. Yet, the present analyses showed no significant intervention effect on fatigue 12-month post-intervention. Accordingly, other randomized intervention trials also saw no maintenance of the intervention effect on fatigue. 24, 25 In the follow-up period, engaging in any (self-reported) exercise was associated with lower physical fatigue compared to no exercise. The causal direction remains unclear, since inactivity could also be a consequence of fatigue. Cognitive and affective fatigue showed some reductions with exercise too, but associations were less consistent than with physical fatigue. Our results strengthen a recent meta-analysis including six intervention Besides the listed factors all models were adjusted for pre-diagnostic fatigue rating (scale 0-10), age (continuous), triple negative tumor (yes/no), and hormone therapy (yes/no).
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2 CT: at T0 already 1-2 chemotherapy cycles, chemotherapy ended typically around T2; no CT(1RT): received no chemotherapy but radiotherapy started shortly after T0 and ended at T1; previous CT(1RT): had received a previous adjuvant or neoadjuvant chemotherapy before T0; radiotherapy started shortly after T0 and ended at T1. 3 Any sports and exercise within the past month (beyond the resistance training during the intervention), excluding walking and cycling for transportation.
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T4 assessment was performed only in the BEST-Study.
Cancer Epidemiology Table 4 . Mixed models regression analyses Besides the listed factors all models were adjusted for pre-diagnostic fatigue rating (scale 0-10), age (continuous), triple negative tumor (yes/no), and hormone therapy (yes/no).
Cancer Epidemiology
Schmidt et al. Table 5 . Mixed models regression analyses Besides the listed factors all models were adjusted for pre-diagnostic fatigue rating (scale 0-10), age (continuous), triple negative tumor (yes/no), and hormone therapy (yes/no).
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studies that found beneficial effects of exercise during adjuvant breast cancer treatment on physical fatigue, but no effects on cognitive and affective fatigue. 26 Obesity was a strong determinant of physical and also of cognitive fatigue, mainly in the post-treatment period. Obesity has been associated with post-treatment or long-term fatigue also in previous studies, [27] [28] [29] especially with the physical but not with the affective or cognitive dimensions. 8 Obese women possibly are less trained and thus get more fatigued physically. Potential pathways also might include inflammation, as adipose tissue had been associated with higher proinflammatory factors which have been associated with fatigue. 30 In obese breast cancer survivors with physical fatigue exercise combined with dietary interventions might be worth further investigation.
All fatigue dimensions were significantly associated with poor sleep quality especially post-therapy. Fatigue and sleep disturbances have frequently been observed to co-occur. 31, 32 The causal direction is unclear. Current evidence including a longitudinal study suggests that sleep disturbance might be a risk factor for cancer-related fatigue. 4, 33 A causal direction might be further suggested by behavioral interventions to improve sleep that also reduced fatigue. 34 Therefore, in fatigued patients sleep disturbances should be addressed. Relaxing acupressure might be an option that had shown significant improvements of sleep quality and persistent fatigue in a randomized trial in 270 breast cancer survivors. 35 Hot flashes were associated with physical and cognitive fatigue at several time points. The association between hot flashes and physical and cognitive fatigue has not been fully investigated. However, strong associations have been observed between fatigue post-treatment and general menopausal symptoms, 36 and between hot flashes and mood and sleep disturbances. 37 Endogenous estrogen withdrawal related to chemotherapyinduced ovarian disruption or hormone therapies might be a common cause for hot flashes as well as fatigue, because estrogen fluctuations alter central levels of norepinephrine and serotonin which might disturb thermoregulation 37 and might also be a possible cause for fatigue. 38, 39 Acupuncture is one possible approach that has shown significant improvements for hot flashes in breast cancer survivors 40 and for fatigue, but evidence is not yet convincing. 41 Previous use of psychopharmaceuticals as an indicator of potential pre-existing mental problems was linked with higher levels of all fatigue dimensions during and several months post-therapy. At baseline 23 patients reported current use psychopharmaceuticals, which comprised mainly antidepressants such as citalopram, amitriptylin, or mirtazapin, and few cases (7 patients) with lorazepam or bromazepam. Those 23 patients had significantly higher depression scores at each timepoint compared to the other patients and reported higher pre-diagnosis fatigue levels. In accordance with our results, strong associations of pre-existing mental/ depressive symptoms with physical, affective, and cognitive long-term fatigue and increased fatigue levels during therapy have been previously shown. 8 It might be debatable, if fatigue in patients with pre-existing mental problems is directly cancer-related or rather related to pre-existing depression, or whether these patients might have metabolic or genetic conditions predisposing them on higher risk for persistent fatigue in all dimensions. Also, the psychopharmaceuticals itself may have contributed to an increase in fatigue. In either case, fatigued patients with a history of mental problems or use of psychopharmaceuticals should be thoroughly monitored for depressive symptoms and accordingly treated. 42 In contrast to physical fatigue, for affective fatigue exercise, BMI, and chemotherapy played no substantial role. Affective fatigue was mainly associated with psycho-social factors such as mental problems, being worried about the future, and lack of social support. Conversely, lack of social support was not a consistent determinant for physical or cognitive fatigue. Similarly, a previous study had observed associations between loneliness (the experience of perceived social isolation, which is associated with perceived lack of social support) and emotional and mental fatigue but not with physical fatigue. 43 Therefore, patients with mainly affective fatigue might especially benefit from support groups and cognitive-behavioral interventions. 2 Our results contribute to the currently sparse knowledge regarding correlates of the separate fatigue dimensions. Strengths of our study include the repeated prospective assessments of fatigue up to 12 months post-treatment with excellent follow-up rates.
As these were secondary analyses of two parallel-randomized trials, all analyses have to be considered exploratory in nature and hence no adjustment for multiple testing was done. A limitation might be lack of generalizability, because the study population comprised patients that were willing to participate in an exercise intervention concomitant to therapy. Further, use of psychopharmaceuticals at baseline was self-reported with incomplete information about continuation during follow-up, and is only a crude surrogate for preexisting mental diseases. Likewise, exercise after the intervention period was only self-reported and thus might be prone to over-reporting.
In conclusion, determinants and courses of fatigue in breast cancer survivors differed for physical, affective, and cognitive fatigue. Thus, fatigue may not effectively be treated with a one-size-fits-all approach. For physical fatigue exercise seems beneficial. Exercise in conjunction with a dietary intervention may be worth further investigation particularly for obese women. If fatigue manifests mainly as affective fatigue then psychosocial interventions might be considered. If fatigue occurs along with poor sleep quality or hot flashes, relief from these symptoms will possibly also improve fatigue. Women with preexisting mental disorders may need special symptomatic treatment.
Overall, fatigue in cancer patients needs to be recognized as a diversity of symptoms with specific characteristics and likely different etiologies, to enable better and more individualized intervention strategies.
